Skip to content

US · RLMD · BIOTECHNOLOGY

Relmada Therapeutics, Inc. (RLMD) intrinsic value and stock valuation

$2.62as of 2026-11-21 · Mkt cap 570.6M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Relmada Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values RLMD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RLMD’s statements →

Relmada Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Coral Gables, FL 33134 relmada.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$0.00
20122025
Net income
-$-57.39M
20122025
Free cash flow
-$-45.79M
20122025
Total equity
$86.5M-3.9% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-59.1M-$-83.89M-$-103.7M-$-161.25M-$-125.7M
Net income-$-57.39M-$-79.98M-$-98.79M-$-157.04M-$-125.75M
EPSd-$-1.45M-$-2.65M-$-3.28M-$-5.3M-$-7.17M
Operating cash flow-$-45.79M-$-51.76M-$-51.66M-$-103.8M-$-91.87M
Capital expenditure$0.00$0.00-$0.00$0.00$0.00
Free cash flow-$-45.79M-$-51.76M-$-51.66M-$-103.8M-$-91.87M
Total assets$94M$45.8M$97.6M$152.9M$223.3M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-3.5M-$-3.86M-$-4.09M-$-5.4M-$-44.44M
Total equity$86.5M$35.5M$85.4M$140.4M$208.3M
Cash and short-term investments$93M$44.9M$96.3M$148.3M$211.9M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$740K$46.2M$54.8M$113.3M$90.6M
Selling, general and administrative expenses$310K$37.7M$48.9M$47.9M$35.1M
Other expenses$58M$0.00$0.00$0.00$0.00
Operating expenses$59.1M$83.9M$103.7M$161.3M$125.7M
Cost and expenses$59.1M$83.9M$103.7M$161.3M$125.7M
Interest income$1.4M$3.53M$5.15M$2.66M$1.2M
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$103.7M$0.00$0.00
Ebitda-$-57.39M-$-79.98M$4.91M-$-157.04M-$-125.75M
Operating income-$-59.1M-$-83.89M-$-103.7M-$-161.25M-$-125.7M
Total other income/expenses, net$1.72M$3.91M$4.91M$4.21M-$-50K
Income before tax-$-57.39M-$-79.98M-$-98.79M-$-157.04M-$-125.75M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-57.39M-$-79.98M-$-98.79M-$-157.04M-$-125.75M
Weighted average shares outstanding$39.5M$30.2M$30.1M$29.6M$17.6M
Weighted average diluted shares outstanding$39.5M$30.2M$30.1M$29.6M$17.6M
Balance sheet
20252024202320222021
Cash and short-term investments$93M$44.9M$96.3M$148.3M$211.9M
Net receivables$0.00$0.00$0.00$510K$90K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$94M$45.8M$97.5M$152.9M$223.3M
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$20K$20K$40K$30K$30K
Total assets$94M$45.8M$97.6M$152.9M$223.3M
Accounts payable$1.57M$4.13M$3.51M$5.26M$11.2M
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$6.43M$10.3M$12.2M$12.5M$15.1M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.06M$0.00$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$7.49M$10.3M$12.2M$12.5M$15.1M
Common stock$70K$30K$30K$30K$30K
Retained earnings-$-698.27M-$-640.88M-$-560.9M-$-462.11M-$-305.07M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$86.5M$35.5M$85.4M$140.4M$208.3M
Total investments$89.5M$41.1M$92.2M$142.9M$167.5M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-3.5M-$-3.86M-$-4.09M-$-5.4M-$-44.44M
Cash flow statement
20252024202320222021
Net income-$-57.39M-$-79.98M-$-98.79M-$-157.04M-$-125.75M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$15M$30.2M$43.8M$44.2M$40.5M
Change in working capital-$-3.95M-$-1.58M$3.08M$10.6M-$-7.86M
Accounts receivable$0.00$0.00$510K-$-430K$80K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-2.56M$620K-$-1.76M$420K$2.85M
Net cash provided by operating activities-$-45.79M-$-51.76M-$-51.66M-$-103.8M-$-91.87M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-48.14M$51.6M$50.5M$19.7M-$-54.12M
Common stock issued$93.6M$250K$0.00$42.7M$185.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$93.6M-$-40K-$-100K$45M$187.9M
Net change in cash-$-360K-$-230K-$-1.3M-$-39.05M$42M
Cash at end of period$3.5M$3.86M$4.09M$5.4M$44.4M
Operating cash flow-$-45.79M-$-51.76M-$-51.66M-$-103.8M-$-91.87M
Capital expenditure$0.00$0.00-$0.00$0.00$0.00
Free cash flow-$-45.79M-$-51.76M-$-51.66M-$-103.8M-$-91.87M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Relmada Therapeutics, Inc.

        Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

        CEO
        Sergio Traversa
        Employees
        17
        Beta
        0.46

        Explore

        Frequently asked questions

        What is the intrinsic value of Relmada Therapeutics, Inc. (RLMD)?

        InvestorsCraft does not currently publish an intrinsic value for RLMD. How the IC value is calculated.

        Is RLMD undervalued?

        InvestorsCraft does not publish an undervaluation signal for RLMD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.